新型冠状病毒肺炎危重型患者(脑出血恢复期)治疗用药评价与监护策略  

Evaluation and Monitoring the Medication of Critically Ill Patients with COVID-19 and Cerebral Hemorrhage during Convalescence

作　　者：王颖[1] 朱昆[1] WANG Ying;ZHU Kun(China Japan Union Hospital of Jilin University,Changchun,Jilin 130033,China)

机构地区：[1]吉林大学中日联谊医院药学部,吉林长春130033

出　　处：《中国药物警戒》2020年第4期208-213,共6页Chinese Journal of Pharmacovigilance

基　　金：全国医药经济信息网科技传播创新工程(CMEI2017K P00248)。

摘　　要：目的评价1例脑出血恢复期合并新型冠状病毒肺炎危重型患者治疗药物,为临床用药安全提供借鉴。方法从药效学、临床药理学、不良反应监测评价等方面对该例患者治疗用药进行评价分析,并提出用药监护策略。结果患者治疗用药基本符合新型冠状病毒肺炎诊疗方案。结论新型冠状病毒肺炎危重型患者(脑出血恢复期),临床表现复杂,治疗方案还应考虑脑出血恢复期相关并发症。Objective To evaluate and monitor the medication of one critically ill patient with cerebral hemorrhage during convalescence complicated with COVID-19,so as to privide reference for clinical drug safety.Methods The medication of one patient was analyzed in terms of pharmacodynamics,clinical pharmacology,monitoring and evaluation of adverse reactions,and the drug monitoring strategy was put forward.Results The medication of this patient was basically in line with the diagnosis and treatment of COVID-19.Conclusion The clinical manifestations of critically ill patients with COVID-19 and cerebral hemorrhage during convalescence are complex,so treatment plans should also take into consideration the convalescence related complications of intracerebral hemorrhage.

关 键 词：新型冠状病毒肺炎危重型 脑出血恢复期 用药评价 监护策略 

分 类 号：R978.7[医药卫生—药品]